Today, Feb. 28, GlaxoSmithKline (GSK) announced the proposed listing of Haleon — a new consumer health firm — that is planned following the demerger of GSK’s consumer healthcare business. Before this morning's opening bell, GSK stock was down by 1.24%.
Haleon: Focusing on Consumer Health
According to GSK, Haleon will be set up as an independent company “focused strategy to deliver sustainable above-market growth and attractive returns to shareholders.” Haleon, zeroed in on consumer health, will bring a strong portfolio to the table, including brands like Advil, Centrum, Panadol, Theraflu and more.
Haleon: Listing in July 2022
Following the demerger of GSK’s Consumer Healthcare business, Haleon is expected to list in July 2022 and is projected to deliver annual organic sales growth of around 4-6% in the medium term.
CEO Comments: Growth-Oriented Companies
GSK CEO Emma Walmsley believes Haleon heralds “the most significant corporate change for GSK in the last 20 years,” creating “two new growth companies that will positively impact the health of billions of people.” Walmsley went on to say that the planned demerger “will unlock the potential of both GSK and Haleon,” with Haleon hopefully becoming a “highly successful growth-orientated company.”
